RARE GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Ultragenyx Pharmaceutical Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
Did you know?
Capital expenditures decreased by 14% from FY24 to FY25.
Current Price
$24.77
+0.32%GoodMoat Value
$28.14
13.6% undervaluedProfile
Valuation (TTM)
Market Cap$2.39B
P/E-4.16
EV—
P/B—
Shares Out96.48M
P/Sales3.55
Revenue$673.00M
EV/EBITDA—
Ultragenyx Pharmaceutical Inc (RARE) Quality Analysis
RARE Profitability
Profitability trend analysis coming soon
RARE Growth
Growth trend analysis coming soon
RARE Financial Health
Financial health indicators coming soon
RARE Quality & Fundamental Analysis
Ultragenyx Pharmaceutical Inc (RARE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates Ultragenyx Pharmaceutical Inc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Ultragenyx Pharmaceutical Inc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of -85.44%. Return on assets (ROA) stands at -37.53%.
with a current ratio of 2.48. Operating margin is -79.49%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Ultragenyx Pharmaceutical Inc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.